Figure 2.
Clinical responses to treatment. A, study subjects were followed monthly for serum PSA levels. Bars along the bottom of the graph represent when the patients were receiving treatment. Black bars, ipilimumab + GM-CSF; gray bars, GM-CSF alone. Three of six patients in dose level 5 (patients 02558-19, 02558-20, and 02558-24) had >50% declines in their PSA levels with treatment. B, patients with evaluable disease were followed with CT scans every 3 mo. One of the three patients (patient 02558-24) with the PSA responses had a measurable liver metastasis (arrow) that regressed with treatment.